Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jun;9(6):E540-E542.
doi: 10.21037/jtd.2017.05.32.

Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer

Brennan McCullar  1 , Taylor Alloway  1 , Michael Martin  2
Affiliations
Case Reports

Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer

Brennan McCullar et al. J Thorac Dis. 2017 Jun.

Abstract

Programmed death 1 (PD-1) inhibitors have been shown to increase overall survival in non-small cell lung cancer (NSCLC) patients. HIV patients have increased expression of PD-1 on their T-cell surfaces. We describe a patient with well-controlled HIV and NSCLC who underwent treatment with nivolumab and had a durable complete response (CR) with his viral load remaining undetectable. To date there is only one case report of a cancer patient with melanoma and with HIV treated with a programmed death ligand 1 (PD-L1) inhibitor. The majority of clinical trials involving PD-1 and PD-L1 inhibitors exclude HIV patients.

Keywords: HIV; Nivolumab; metastatic non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Chest X-ray showing right upper lobe mass.
See this image and copyright information in PMC

References

    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. 10.1038/nrc3239 - DOI - PMC - PubMed
    1. Sundar R, Cho BC, Brahmer JR, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 2015;7:85-96. 10.1177/1758834014567470 - DOI - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed
    1. Macatangay BJ, Rinaldo CR. PD-1 blockade: A promising immunotherapy for HIV? Cellscience 2009;5:61-5. - PMC - PubMed
    1. Available online: https://clinicaltrials.gov/

Publication types